S7A Channel Profiling Panel™
Benefits:
- Supports FDA’s Critical Path Initiative – tools for predicting safety & efficacy
- Accurate results provided promptly & economically
Assess Potential Ion Channel-Related Adverse Effects in S7A ICH/FDA Guidance
|
Category
|
Class Effect
|
Adverse Drug Reactions
|
Ion Channel Targets
|
|
Central Nervous System (CNS)
|
Seizures
|
convulsions, syncope
|
Nav1.1, Nav1.2, KCNQ2/KCNQ3, KCNQ3/KCNQ5, CLC-2, Cav3.2, HCN1, GABA-A
|
|
Headache
|
migraine
|
Cav2.1
|
|
Movement disorders
|
dyskinesia, ataxia, myoclonus, tremor, extrapyramidal effects
|
Nav1.6, Kv1.1, BK, SK2, SK3, Cav2.1. NMDA
|
|
Pain
|
inflammation, peripheral neuropathy, hyperalgia
|
ASIC1, Nav1.3, Nav1.7, Nav1.8, Nav1.9, Kv1.3, Kv4.2/KChIP2.2, TRPA1, TRPV1,P2X2, P2X4, P2X7
|
|
Vestibular
|
dizziness, nystagmus
|
Cav1.2, Cav2.2
|
|
Cardiovascular System (CVS)
|
Blood pressure
|
systemic hypertension or hypotension
|
Cav1.2, KV1.5, Sk3, NCX1
|
|
Bradycardia
|
sick sinus syndrome
|
HCN4, Cav3.2
|
|
Tachycardia
|
ventricular arrhythmia, fibrillation, palpitations, supraventricular tachycardia, syncope, torsade de pointes
|
Nav1.5, Kv1.5, Kv4.3, hERG, KvLQT1/minK, Kir2.1, Cav1.2
|
|
Respiratory
|
Pulmonary blood pressure
|
Pulmonary hypertension
|
Cav1.2, Cav2.2
|
|
Lung function
|
Increased airway resistance, Cystic fibrosis
|
BK, CFTR
|
|
Otological
|
Auditory
|
hearing loss, hypoacusis
|
KCNQ4, HCN1, CLC-KB, KvLQT1/minK
|
|
Opthalmic
|
Visual
|
disturbed color vision, retinitis, achromatopsia
|
CNGA1-CNGB1, CNGA3-CNGB3
|
|
Metabolic
|
Pancreatic
|
hypoglycemia
|
KIR6.2/SUR1
|
|
Renal
|
hypokalemia
|
Kir1.1, CLC-KA/barttin, CLC-KB/barttin
|
|
Musculoskeletal
|
Muscle disorder
|
hypotonia, myotonia, spasm, myalgia, myasthenia
|
Nav1.4, Kv1.1, Kv1.2, Kv3.4, SK3, CLC-1, Cav1.1, Cav2.1
|
 SAB-S7A channel profiling panel.pdf
|